RecruitingPhase 3NCT06629779
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Sponsor: Pfizer
The Bronx, NY · +37 more sites
Prostate Cancer clinical trials in The Bronx, NY
13 recruiting prostate cancer studies with a site in The Bronx, NY.
RecruitingPhase 3NCT07028853
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Sponsor: Pfizer
Commack, NY · Harrison, NY · Lake Success, NY · +124 more sites
RecruitingPhase 3NCT03678025
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Sponsor: SWOG Cancer Research Network
Albany, NY · Buffalo, NY · Dansville, NY · +331 more sites
RecruitingPhase 2NCT07287150
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Sponsor: Hoffmann-La Roche
The Bronx, NY · +5 more sites
RecruitingPhase 3NCT07200830
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Sponsor: Alliance for Clinical Trials in Oncology
Buffalo, NY · Commack, NY · Harrison, NY · +135 more sites
RecruitingPhase 3NCT07225946
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Sponsor: Janssen Research & Development, LLC
Mineola, NY · New York, NY · The Bronx, NY · +56 more sites
RecruitingPhase 3NCT05939414
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Sponsor: Novartis Pharmaceuticals
New York, NY · Syracuse, NY · The Bronx, NY · +36 more sites
RecruitingPhase 2 / Phase 3NCT06780670
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Sponsor: Novartis Pharmaceuticals
New York, NY · Syracuse, NY · The Bronx, NY · +32 more sites
RecruitingPhase 2NCT04038502
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Sponsor: VA Office of Research and Development
New York, NY · The Bronx, NY · +16 more sites
RecruitingPhase 1 / Phase 2NCT04104776
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Sponsor: Novartis Pharmaceuticals
Buffalo, NY · New York, NY · +19 more sites
RecruitingPhase 3NCT04423211
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Sponsor: ECOG-ACRIN Cancer Research Group
Bay Shore, NY · Forest Hills, NY · Lake Success, NY · +338 more sites
RecruitingPhase 3NCT06592924
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Sponsor: Canadian Cancer Trials Group
The Bronx, NY · +373 more sites
RecruitingPhase 2NCT05422911
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
Sponsor: Sun Pharmaceutical Industries Limited
New York, NY · The Bronx, NY · Wappingers Falls, NY · +9 more sites
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.